Juluca (dolutegravir, rilpivirine; ViiV Healthcare) maintained viral suppression through 100 weeks in virologically suppressed people living with HIV who switched to the 2-drug regimen from a 3 or 4-drug antiviral regimen, according to pooled data from the SWORD Phase 3 program.
Juluca is a once-daily, single-tablet regimen that combines dolutegravir, an HIV-1 integrase strand transfer inhibitor, and rilpivirine, an HIV-1 non-nucleoside reverse transcriptase inhibitor. The SWORD 1 and SWORD 2 trials enrolled 1027 HIV-infected and virologically suppressed adults; both trials had an early (Day 1 to Week 52) and late (Week 52 to Week 148) switch phase.
Pooled data from both studies showed that through 100 weeks, 89% (N=456/513) of patients in the early phase who received Juluca maintained viral suppression with a viral load of <50 copies/mL.
In the late switch arm, where the current antiretroviral regimen was continued through Week 52 before switching to Juluca, 93% (N=444/477) of patients maintained viral suppression through Week 100.
“This 100-week data should provide physicians with further confidence that they may be able to reduce the number of antiretroviral drugs required to effectively maintain virologic suppression in their patient’s HIV,” said John C. Pottage, Jr., MD, Chief Scientific and Medical Officer, ViiV Healthcare.
Juluca is FDA-approved as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for ≥6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.
For more information visit ViiVHealthcare.com.
This article originally appeared on MPR